Nicole L. YatesAllan C. deCampBette T. KorberHua Xin LiaoCarmela IreneAbraham PinterJames PeacockLinda J. HarrisSheetal SawantPeter HraberXiaoying ShenSupachai Rerks-NgarmPunnee PitisuttithumSorachai NitayapanPhillip W. BermanMerlin L. RobbGiuseppe PantaleoSusan Zolla-PaznerBarton F. HaynesS. Munir AlamDavid C. MontefioriGeorgia D. TomarasUniversity of California, Santa CruzCentre Hospitalier Universitaire VaudoisJinan UniversityArmed Forces Research Institute of Medical Sciences, ThailandThailand Ministry of Public HealthHJFIcahn School of Medicine at Mount SinaiWalter Reed Army Institute of ResearchMahidol UniversityLos Alamos National LaboratoryRutgers New Jersey Medical SchoolDuke University School of MedicineFred Hutchinson Cancer Research Center2019-08-232019-08-232018-04-01Journal of Virology. Vol.92, No.8 (2018)109855140022538X2-s2.0-85044631722https://repository.li.mahidol.ac.th/handle/20.500.14594/44791© 2018 American Society for Microbiology. Induction of broadly cross-reactive antiviral humoral responses with the capacity to target globally diverse circulating strains is a key goal for HIV-1 immunogen design. A major gap in the field is the identification of diverse HIV-1 envelope antigens to evaluate vaccine regimens for binding antibody breadth. In this study, we define unique antigen panels to map HIV-1 vaccine-elicited antibody breadth and durability. Diverse HIV-1 envelope glycoproteins were selected based on genetic and geographic diversity to cover the global epidemic, with a focus on sexually acquired transmitted/founder viruses with a tier 2 neutralization phenotype. Unique antigenicity was determined by nonredundancy (Spearman correlation), and antigens were clustered using partitioning around medoids (PAM) to identify antigen diversity. Cross-validation demonstrated that the PAM method was better than selection by reactivity and random selection. Analysis of vaccine-elicited V1V2 binding antibody in longitudinal samples from the RV144 clinical trial revealed the striking heterogeneity among individual vaccinees in maintaining durable responses. These data support the idea that a major goal for vaccine development is to improve antibody levels, breadth, and durability at the population level. Elucidating the level and durability of vaccine-elicited binding antibody breadth needed for protection is critical for the development of a globally efficacious HIV vaccine.Mahidol UniversityAgricultural and Biological SciencesImmunology and MicrobiologyArticleSCOPUS10.1128/JVI.01843-17